Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.62 |
| ▸ | GANAB | Q14697 | 1/20 | 0.62 |
| ▸ | GLB1 | P16278 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | AGL | P35573 | 2/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.43 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19328384 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL2434766 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL9495785 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL14246910 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL7032907 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL23531404 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL2265142 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| Hydrochloric Acid SCHEMBL9496174 | 0.98 | GBA1 (0.60) | GBA1GANABGLB1MGAMGAA | |
| Hydrochloric Acid SCHEMBL9497390 | 0.98 | GBA1 (0.60) | GBA1GANABGLB1MGAMGAA | |
| Hydrochloric Acid SCHEMBL960466 | 0.98 | GBA1 (0.60) | GBA1GANABGLB1MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038373-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2023-02-09 | — | — | US | claimed |
| US-20210402002-A1 | CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-12-30 | — | — | US | claimed |
| WO-2021123506-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-06-24 | — | — | WO | claimed |
| CN-112672764-A | Conjugates | 格莱科斯生物医药公司 | 2021-04-16 | — | — | CN | claimed |
| US-20180051069-A1 | COMPOSITIONS AND METHODS FOR TREATING ALLERGIC INFLAMMATION | THE GENERAL HOSPITAL CORPORATION (US) | 2018-02-22 | — | — | US | claimed |
| WO-2016144760-A1 | COMPOSITIONS AND METHODS FOR TREATING ALLERGIC INFLAMMATION | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-15 | — | — | WO | claimed |
| WO-2008068548-A1 | USE OF INHIBITORS OF THE GLYCOSYLATION PROCESS FOR THE PREVENTION AND TREATMENT OF GENETIC DISEASES | INSTITUT NECKER (FR) | 2008-06-12 | — | — | WO | claimed |
| EP-0938286-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2003-11-05 | — | — | EP | claimed |
| US-5908867-A | Reduction of hair growth | HENRY JAMES P (US) | 1999-06-01 | — | — | US | claimed |
| EP-0424350-B1 | Derivatives of 1,4-dideoxy-1,4-imino-d-mannitol | MONSANTO CO (US) | 1995-02-01 | — | — | EP | claimed |
| US-5075457-A | Synthesis of swainsonine and analogs thereof | MONSANTO COMPANY (US) | 1991-12-24 | — | — | US | claimed |
| US-5041555-A | Mannosidase inhibitors | MONSANTO COMPANY (US) | 1991-08-20 | — | — | US | claimed |
| EP-0424350-A1 | Derivatives of 1,4-dideoxy-1,4-imino-d-mannitol | MONSANTO COMPANY (US) | 1991-04-24 | — | — | EP | claimed |
| EP-0424349-A1 | Synthesis of 1,4-dideoxy-1,4-imino-D-mannitol | MONSANTO COMPANY (US) | 1991-04-24 | — | — | EP | claimed |
| US-20260027213-A1 | EPICARDIAL-DERIVED PARACRINE FACTORS FOR REPAIRING CARDIAC TISSUE | REGENCOR INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12458689-B2 | Escherichia coli compositions and methods thereof | PFIZER INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4608859-A1 | GLYCOENGINEERED FC VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION | Ablynx N.V. (BE) | 2025-09-03 | — | — | EP | disclosed |
| US-4996329-A | Enzyme inhibitors, viricides | MONSANTO COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
| US-4996329-A | Enzyme inhibitors, viricides | MONSANTO COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
| US-4996329-A | Enzyme inhibitors, viricides | MONSANTO COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210402002-A1 | CONJUGATE | ST6GAL1, CSGALNACT1, FUT6 | GBA1 118/4885GANAB 311/4885GLB1 270/4885 |
| US-12458689-B2 | Escherichia coli compositions and methods thereof | MRPL21, DDOST, OSTC | GBA1 2642/4885GANAB 1849/4885GLB1 283/4885 |
| US-20260027213-A1 | EPICARDIAL-DERIVED PARACRINE FACTORS FOR REPAIRING CARDIAC TISSUE | TNNI3, TNNT2, FN1 | GBA1 3902/4885GANAB 2246/4885GLB1 3365/4885 |
| US-20230038373-A1 | STABILE CONJUGATE | CD2, TTL, DDOST | GBA1 334/4885GANAB 613/4885GLB1 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.